Gravity-Powered Biomedical Device Paves Way for Low Cost POC Diagnostic Testing
|
By LabMedica International staff writers Posted on 14 Jul 2023 |

The need for simple, user-friendly, point-of-care devices continues to exist. Many prototype and market-ready devices aim to simplify diagnosis and crucial biomarker measurement processes using minimal liquid samples, power, and professional knowledge. These innovations aim to enhance healthcare delivery for the vast population residing in low-resource locales, far from well-equipped hospitals and qualified medical personnel. These tests generally share certain prerequisites: they need to transport, combine, and assess minute biological sample-containing droplets and their active ingredients, enabling specific biomarker measurements. High-end devices employ miniature electric pumps to facilitate these reactions, while others leverage the dynamics of liquids within microchannels, or microfluidics, to produce a suction-like effect. Each method comes with its own distinct benefits and challenges. Now, researchers have demonstrated a first-of-its-kind approach that only uses gravity to power point-of-care biomedical devices and also offers certain advantages over currently existing platforms.
Biomedical engineers at Duke University (Durham, NC, USA) have devised a completely new approach for building point-of-care diagnostic tools, which only leverages gravity to transport, mix, and manipulate the liquid droplets involved. This proof-of-concept uses readily available materials and minimal power to interpret results, making it a potentially beneficial option for use in settings with limited resources. The innovative gravity-based technique is based on a selection of nine commercially available surface coatings that can fine-tune the wettability and slipperiness at any given point in the device, thereby controlling how much droplets spread into pancakes or remain spherical, while also influencing their ease of movement down an incline.
By using these surface coatings in smart combinations, all necessary microfluidic elements required for a point-of-care test can be generated. For instance, if a certain location is extremely slippery and a droplet is positioned at a juncture where one side pulls liquid flat and the other pushes it into a ball, it acts like a pump and accelerates the droplet toward the former. The scientists devised numerous elements to manage the motion, interaction, timing, and sequence of multiple droplets within the device. Merging these elements, they fabricated a prototype test to measure human serum lactate dehydrogenase (LDH) levels. They carved channels into the testing platform to create designated routes for droplet passage, each coated with a substance preventing droplets from sticking along the way. Specific points were also pre-treated with dried reagents needed for the test, which are absorbed by droplets of simple buffer solution as they traverse the channels.
The maze-like test is then sealed with a lid equipped with holes for the sample and buffer solution to be dripped in. Once filled, the test is inserted into a box-shaped device with a handle that rotates the test by 90 degrees, allowing gravity to take over. The device also features a simple LED and light detector for swift and easy color-based test result assessment. This enables the scientists to label three different biomarkers with distinct colors for varying tests. In the LDH prototype test, the biomarker is marked with a blue molecule. A basic microcontroller measures the depth of the blue tint and the rate of color change, signifying the quantity and concentration of LDH in the sample, to yield results. This novel demonstration presents a new approach to the development of affordable, low-energy, point-of-care diagnostic devices. While the team intends to further refine their concept, they also hope it will spark interest and lead to the creation of similar tests by other researchers.
“Most microfluidic devices need more than just capillary forces to operate,” said Ashutosh Chilkoti, the Alan L. Kaganov Distinguished Professor of Biomedical Engineering at Duke. “This approach is much simpler and also allows very complex fluid paths to be designed and operated, which is not easy or cheap to do with microfluidics.”
Related Links:
Duke University
Latest Technology News
- Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read moreMolecular Diagnostics
view channel
Circular RNAs Enable Noninvasive Cancer Detection and Risk Assessment
Liquid biopsy promises earlier cancer detection and agile treatment monitoring, but robust biomarkers that are stable and disease‑specific remain a hurdle. Circular RNAs (circRNAs) are structurally resilient... Read more
Polygenic Risk Score Test Estimates Inherited Coronary Artery Disease Risk
Early identification of individuals with an inherited predisposition to coronary plaque can inform earlier evaluation of coronary artery disease risk, particularly among younger adults who may develop... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelPartnership Brings Automated Pathology Archiving Solutions to U.S. Labs
Accurate retention and retrieval of pathology blocks and slides underpin timely, reliable cancer diagnoses, yet manual archiving remains labor-intensive and error-prone for many laboratories.... Read more







